Zenagamtide vs CagriSema: Single Molecule vs Fixed-Dose Combination

Why both? Obesity is now Novo Nordisk’s largest growth engine and one of the fastest-expanding categories in the broader pharma market. CEO Maziar Mike Doustdar has been explicit about the playbook: push existing GLP-1 doses higher and seed new mechanism classes — amylin receptor agonism in particular — rather than betting the franchise on a single asset. CagriSema is the near-term entrant; zenagamtide (amycretin) is the explicit post-2027 follow-on. Same strategy on two different timelines.

Are Amycretin and CagriSema the Same Drug?

Short answer: no. They share a mechanism of action — dual activation of GLP-1 and amylin receptors — and they share a developer in Novo Nordisk. Past that, the two compounds diverge. Zenagamtide — the name Novo Nordisk now uses publicly (the molecule’s development code was amycretin, NN9487) — is a single unimolecular peptide engineered so that one molecular backbone activates both receptor families. CagriSema is a fixed-dose combination: two separate peptides — cagrilintide (a long-acting amylin analog) and semaglutide (the GLP-1 receptor agonist already on market as Ozempic and Wegovy) — delivered together (now via dual-pen, after Novo abandoned the single-chamber co-formulated device).

The distinction is more than academic. CagriSema and amycretin are fundamentally different approaches to dual GLP-1/amylin receptor activation, and that drives four downstream differences: manufacturing complexity, dosing flexibility, pharmacokinetic profile, and long-term development potential (oral delivery, in particular). Two competing answers to the same biological question, both running inside the same company.

What Is Zenagamtide (Amycretin), the Dual GLP-1/Amylin Receptor Agonist?

Zenagamtide is Novo Nordisk’s unimolecular dual GLP-1/amylin receptor agonist — a single peptide built to activate both receptor families simultaneously. Novo Nordisk now uses zenagamtide as the public name, presenting data under it at the ADA 2026 Scientific Sessions; amycretin was the molecule’s development code (NN9487). It is engineered to cross the blood-brain barrier and act on the central appetite circuits that regulate energy intake, which is the same mechanistic route as the rest of the incretin class. It is being evaluated for obesity and type 2 diabetes across a slate of trials initiated through 2024 and 2025. In the published Phase 1b/2 readout, subcutaneous amycretin produced approximately 22% mean weight loss over roughly 36 weeks. Our amycretin compound profile walks through the mechanism, trial enrollment, and dose-escalation data in detail.

The Phase 3 picture is now active. The AMAZE programme for obesity is enrolling, and in May 2026 Novo Nordisk launched AMAZE-12 — a Phase 3 trial of amycretin specifically for weight maintenance after diet-induced weight loss, the first amycretin Phase 3 obesity-maintenance study (source). Internally, Novo positions zenagamtide as the post-2027 obesity follow-on to CagriSema in its pipeline (source). At the ADA 2026 Scientific Sessions (June 2026), Novo presented positive Phase 2 data for once-weekly subcutaneous zenagamtide in type 2 diabetes: statistically significant A1C reductions (up to 1.71 percentage points, with 89.1% of participants reaching A1C below 7%) and up to 14.6% body-weight loss at week 36 on the highest 40 mg dose (source).

Beyond weight, early data also suggest amycretin reduces liver fat and lowers inflammatory markers in metabolic dysfunction-associated steatotic liver disease (MASLD) — an active secondary endpoint in the broader programme. Tolerability tracks the rest of the class: the most commonly reported adverse events in the Phase 1b/2 cohort were gastrointestinal (nausea and vomiting), concentrated during dose escalation.

The more strategically important asset may be the oral formulation. Novo Nordisk has an oral version of amycretin in Phase 2 (trial registration pending on ClinicalTrials.gov). If those trials read out positively, amycretin would be one of the first oral dual GLP-1/amylin agonists to reach the market — a meaningful structural advantage over any injection-only competitor, including CagriSema. Amycretin also holds an orphan drug designation alongside its broader obesity development program.

What Is CagriSema?

CagriSema is Novo Nordisk’s fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist). The Phase 3 REDEFINE program reported 22.7% mean weight loss in REDEFINE 1 (obesity, no diabetes) and 15.7% in REDEFINE 2 (type 2 diabetes).

The Feb 23, 2026 REDEFINE-4 open-label head-to-head told a more complicated story: CagriSema delivered 20.2% mean weight loss versus 23.6% for tirzepatide at 84 weeks — the primary non-inferiority endpoint was not achieved (source). That outcome reframes CagriSema’s positioning against the incumbent rather than ahead of it.

Novo Nordisk filed the New Drug Application (NDA) with the FDA on December 18, 2025 — the company’s most advanced dual-receptor obesity asset and the first once-weekly GLP-1/amylin combination to reach a regulatory submission. An FDA decision is expected in late 2026. Novo has also abandoned the planned single-chamber co-formulated CagriSema device; the launch will now use a dual-pen approach with the two components delivered separately. Because CagriSema is a fixed-dose combination, the cagrilintide-to-semaglutide ratio is locked at the formulation level: clinicians can move the total dose, but they cannot tune the two components independently. The full REDEFINE dataset is broken down in our CagriSema profile.

How Do Their Approaches to Body Weight Differ?

Architecturally, the two programs sit on opposite sides of a design choice. CagriSema is a co-formulation play: take two molecules with substantial independent clinical evidence (cagrilintide and semaglutide), set a fixed ratio, and put them in one delivery system — now a dual-pen, after Novo abandoned the single-chamber co-formulated device. The upside is that both components arrive with their own safety and efficacy histories. The downside is that the ratio is locked, and the manufacturing line has to produce, purify, and stabilize two peptides instead of one.

Amycretin is the inverse: rather than combining two molecules, engineer a single peptide with both activities encoded into one structure. The receptor balance is built into the molecule rather than negotiated by mixing. The trade-off is that the molecule is novel, the chemistry is more demanding, and Phase 3 efficacy data has not yet been reported. For how both compare against next-generation triple agonists, see our retatrutide vs tirzepatide vs CagriSema breakdown.

Why Does the Single-Molecule Design Matter in Late-Stage Trials?

Three downstream advantages flow from packing both activities into one peptide. Manufacturing is simpler — there is only one molecule to synthesize, purify, and characterize, instead of two separate active pharmaceutical ingredients held to a strict combination spec. Pharmacokinetic optimization is cleaner because both effects ride the same absorption and clearance profile, rather than relying on two molecules with potentially divergent half-lives.

The biggest payoff, though, is oral delivery. Building an oral version of a fixed-dose combination would mean solving the oral absorption problem twice — once for each peptide — and then preserving a fixed ratio across both. A single molecule sidesteps that. Amycretin’s oral Phase 2 program is the practical demonstration: the unimolecular design is what makes the oral pathway tractable. For an amylin-only counterpoint, see our petrelintide research breakdown.

What Does This Mean for Novo Nordisk’s Obesity Market Pipeline?

Novo Nordisk is running a deliberate two-generation strategy. CagriSema is the near-term commercial bet — NDA filed Dec 18, 2025, FDA decision expected late 2026, dual-pen launch device. After REDEFINE-4 came in 20.2% vs tirzepatide’s 23.6%, CagriSema is no longer positioned as a tirzepatide-beater but as a credible GLP-1/amylin entrant defending the existing Wegovy franchise.

Amycretin is the explicit post-2027 follow-on. Novo has framed it that way in its own pipeline communications. Its Phase 3 AMAZE programme is enrolling, the May 2026 AMAZE-12 launch adds a weight-maintenance indication, and its unimolecular design plus oral development programme give it a clear successor profile. If the Phase 3 readouts confirm that one molecule can match or beat a two-molecule combination — particularly in oral form — amycretin could become Novo Nordisk’s preferred GLP-1/amylin asset over the next decade. The REDEFINE-4 miss arguably strengthens the strategic case for amycretin as the successor asset.

Running a near-term program and a next-generation successor in the same indication is standard pharmaceutical strategy. It hedges the launch risk on CagriSema, gives Novo Nordisk a structural lead in the oral GLP-1/amylin race, and keeps the company in step with the broader incretin pipeline. Regional context: in May 2026 Novo Nordisk also announced a UAE logistics hub, flagging the Middle East as a growth region for its obesity portfolio (source) — logistics scope, not a UAE clinical or regulatory milestone for either compound. For the wider competitive landscape, see our obesity drug approval tracker 2026 and the best obesity drug 2026 comparison.